AMPH Amphastar Pharmaceuticals, Inc.

+1  (4%)
Previous Close 13.75
Open 13.70
Price To book 1.93
Market Cap 656.75M
Shares 46,023,000
Volume 277,668
Short Ratio 6.40
Av. Daily Volume 410,087

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Albuterol DPI
CRL announced February 21, 2017.
Naloxone Intranasal
Opioid overdose
CRL issued December 27, 2016.
Primatene Mist (epinephrine inhalation aerosol)

Latest News

  1. Amphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  2. Amphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
  4. Edited Transcript of AMPH earnings conference call or presentation 13-Mar-17 9:00pm GMT
  5. AMPHASTAR PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
  6. Amphastar Pharmaceuticals downgraded by Raymond James
  7. Amphastar reports 4Q loss
  8. Amphastar reports 4Q loss
  9. AMPHASTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
  10. Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2016
  11. Williams-Sonoma Among 5 Earnings Plays That Could Squeeze the Shorts
  12. Q4 2016 Amphastar Pharmaceuticals Inc Earnings Release - After Market Close
  13. Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 13, 2017
  14. Drug Addiction Treatment Stocks to Watch
  15. Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : February 22, 2017
  16. FDA Rejects Amphastar's Nasal Opioid Overdose Drug
  17. Amphastar Pharma stock plummets 16% after FDA fails to approve nasal spray for opioid overdoses
  18. FDA rejects Amphastar's nasal version of opioid overdose treatment
  19. Amphastar Announces the Receipt of a CRL for Intranasal Naloxone for the Emergency Treatment of Opioid Overdose
  20. Lifshitz & Miller Law Firm Announces Investigation of Ally Financial Inc., Amphastar Pharmaceuticals, Inc., Lannett Company, Inc., Live Ventures Incorporated, MiMedx Group, Inc., Seattle Genetics, Inc., Teligent, Inc., TerraVia Holdings, In